top of page
pexels-pixabay-265987(1).jpg

PGT-A

Preimplantation Genetic Testing for Aneuploidy 

Preimplantation Genetic Testing for Aneuploidy (PGT-A) is an advanced reproductive technology used during in vitro fertilization (IVF) to screen embryos for chromosomal abnormalities. Aneuploidy refers to an abnormal number of chromosomes, which can lead to implantation failure, miscarriage, or genetic disorders such as Down syndrome. By identifying chromosomally normal embryos, PGT-A aims to improve the chances of a successful pregnancy and healthy live birth.

​Indications for PGT-A

PGT-A is recommended for individuals or couples in the following situations:
jonathan-borba-Z39a7lqZusU-unsplash(1).jpg

Advanced Maternal Age (≥35 years)

Risk of embryonic aneuploidy increases with age.

Recurrent Pregnancy Loss

Multiple miscarriages may indicate chromosomal abnormalities in embryos.

Repeated IVF Failure

Unexplained failed implantation cycles.

​Balanced Chromosomal Rearrangements

Carriers of translocations or inversions (though PGT for structural rearrangements is technically PGT-SR).

Family Planning

To reduce the risk of transferring embryos with severe chromosomal disorders.

​Benefits of PGT-A​

cells-1872666_1280(1).jpg

Higher Pregnancy Rates

Reduces the likelihood of transferring embryos with lethal abnormalities.

​Lower Miscarriage Risk

Aneuploidy accounts for ~50% of early miscarriages; PGT-A minimizes this risk.

Reduced Time to Pregnancy

Avoids multiple unsuccessful transfers.

Single Embryo Transfer (SET)

Lowers the risk of multiples (twins/triplets) while maintaining success rates.

​Informed Decision-Making

Provides clarity for patients with recurrent IVF failures or genetic concerns.

How It Works:PGT-A

Discover the sequential process of PGT - A, from the initial IVF cycle to the final selection of chromosomally normal embryos for a higher chance of successful implantation.

close-up-scientist-working-with-microscope(1).jpg
  • Eggs are retrieved, fertilized with sperm, and cultured to the blastocyst stage (Day 5–6).

  • A few cells from the trophectoderm (future placenta) are gently removed for genetic analysis.

  • Using next-generation sequencing (NGS) or microarray technology, the cells are screened for chromosomal abnormalities (e.g., missing or extra chromosomes).

  • Only euploid (chromosomally normal) embryos are selected for transfer, optimizing implantation success.

bottom of page